使用诊断性腹腔镜对晚期卵巢癌进行肿瘤活检的临床可行性
Clinical Availability of Tumour Biopsy Using Diagnostic Laparoscopy for Advanced Ovarian Cancer.
作者信息
Odajima Suguru, Ueda Kazu, Hosoya Satoshi, Tomita Keisuke, Kato Sayako, Shoburu Yuichi, Kawabata Ayako, Iida Yasushi, Yanaihara Nozomu, Okamoto Aikou
机构信息
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan;
出版信息
In Vivo. 2021 Nov-Dec;35(6):3325-3331. doi: 10.21873/invivo.12629.
BACKGROUND/AIM: Tumour biopsy using laparoscopy before neoadjuvant chemotherapy for advanced ovarian cancer has been widely accepted. However, there are few reports about its operative outcome compared to biopsy with laparotomy. We investigated the advantage of laparoscopic biopsy for advanced ovarian cancer.
PATIENTS AND METHODS
We included 23 patients who underwent laparoscopy and 27 who underwent exploratory laparotomy before neoadjuvant chemotherapy between January 2012 and August 2020. We reviewed their medical records and evaluated their operative outcomes.
RESULTS
Blood loss was significantly lower in the laparoscopy group (5 ml vs. 320 ml, p<0.05). The period until the initiation of neoadjuvant chemotherapy was significantly shorter in the laparoscopy group (12 days vs. 16 days, p<0.05). Overall survival did not differ significantly between the two groups (25.4 months vs. 24.7 months, p=0.53).
CONCLUSION
Laparoscopic tumour biopsy is useful and safe for histological diagnosis, thereby allowing for early introduction to neoadjuvant chemotherapy.
背景/目的：对于晚期卵巢癌，在新辅助化疗前采用腹腔镜进行肿瘤活检已被广泛接受。然而，与开腹活检相比，关于其手术结果的报道较少。我们研究了腹腔镜活检在晚期卵巢癌中的优势。
患者与方法
我们纳入了2012年1月至2020年8月期间在新辅助化疗前行腹腔镜检查的23例患者以及行开腹探查的27例患者。我们回顾了他们的病历并评估了手术结果。
结果
腹腔镜组的失血量显著更低（5毫升对320毫升，p<0.05）。腹腔镜组开始新辅助化疗的时间显著更短（12天对16天，p<0.05）。两组的总生存期无显著差异（25.4个月对24.7个月，p=0.53）。
结论
腹腔镜肿瘤活检对于组织学诊断是有用且安全的，从而能够尽早开始新辅助化疗。
Zotero 插件